MétaCan
Menu
← Back to cohort
Record W4412501589 · doi:10.1002/alz.70470

Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies

2025· review· en· W4412501589 on OpenAlexaff
Jennifer G. Goldman, Bradley F. Boeve, Douglas Galasko, John‐Paul Taylor, James E. Galvin, James B. Leverenz, ‪Frederic Blanc‬, Glenda M. Halliday, Kejal Kantarci, Afina W. Lemstra, Iracema Leroi, Simon J.G. Lewis, Irene Litvan, Helen Bundy Medsger, John T. O’Brien, Sonja W. Scholz, Dag Aarsland, Manabu Ikeda, Ian G. McKeith, Angela E. Taylor

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typereview
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsCentre for Movement Disorders
FundersNational Institute on AgingLewy Body Dementia AssociationDemensförbundet
KeywordsDementia with Lewy bodiesDiseaseNeurodegenerationDementiaMedicineParkinson's diseaseNeuroscienceBiomarkerNeurochemicalSynucleinopathiesAlpha-synucleinLewy bodyAlzheimer's diseaseDopaminergicPathologyPsychologyBiologyDopamine

Abstract

fetched live from OpenAlex

Dementia with Lewy bodies (DLB), a progressive neurodegenerative disease with heterogeneous clinical presentations, greatly impacts patients, caregivers, and society. Despite its frequency, diagnosing and treating DLB remains challenging. Advances in in vivo biomarker assays reflecting underlying pathology are improving disease identification, diagnostic accuracy, and therapeutic development for biologically targeted, disease-modifying agents. Consequently, definitions of Alzheimer's disease and Parkinson's disease (PD) have shifted to focus on pathological changes occurring before clinical features, with proposed frameworks for detecting pathological amyloid and tau, neurodegeneration, and other markers (National Institute on Aging-Alzheimer's Association) and alpha-synucleinopathy and dopaminergic degeneration (Neuronal α-synuclein Disease Integrated Staging System, SynNeurGe). The biological frameworks, particularly those related to alpha-synuclein (α-synuclein), have sparked debate about unifying DLB and PD under a single pathobiologic disease. This paper discusses the implications of these biological frameworks for the DLB community, addressing topics regarding multiple pathologies and neurochemical systems, clinical heterogeneity, and functional impairment, and exploring the potential impact on clinical trials and care. HIGHLIGHTS: DLB is a progressive neurodegenerative disease with varied clinical presentations. Diagnosing and treating DLB remains challenging despite its frequency. Biological frameworks are reshaping Alzheimer's and Parkinson's definitions. In vivo biomarkers are improving DLB identification and diagnostic accuracy. Debate exists regarding unifying DLB and Parkinson's under one pathobiology.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.020
metaresearch head score (Gemma)0.025
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.020
Threshold uncertainty score0.104

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0200.025
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0030.002
Science and technology studies0.0040.030
Scholarly communication0.0090.017
Open science0.0030.007
Research integrity0.0070.011
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.095
GPT teacher head0.337
Teacher spread0.242 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicParkinson's Disease Mechanisms and Treatments→French-language works237,207→